Literature DB >> 27743032

Small cell-like glandular proliferation of prostate: a rare lesion not related to small cell prostate cancer.

Oleksandr N Kryvenko1,2,3, Sean R Williamson4,5, Kiril Trpkov6, Nilesh S Gupta4, Daniel Athanazio6, Martin K Selig7, Paul Taylor Smith8, Cristina Magi-Galluzzi9, Merce Jorda8,10,11.   

Abstract

Small cell-like change (SCLC) is a rare prostate lesion which has been described in only two previous studies (total of eight cases). Its relation to possible neuroendocrine differentiation remained unclear. We evaluated 11 SCLC cases with immunohistochemistry and electron microscopy. SCLC was characterized by crowded hyperchromatic small nuclei with scant cytoplasm, rosette-like structures, finely granular chromatin with indistinct nucleoli, and lack of mitoses, apoptoses, and necroses. In nine cases, SCLC was admixed with high-grade cancer, and in two cases, it represented a separate intraductal process, spatially remote from a low-volume Gleason score 6 (grade group 1) cancer. Only 2/11 SCLC labeled for synaptophysin, chromogranin, and serotonin, although 6/11 were at least focally positive for TTF1. Staining for NKX3.1 and pancytokeratin was typically weak, focal, and markedly reduced compared to the adjacent cancer. SCLC was positive for ERG in 1/8 and for racemase in 6/10 cases, again typically in a focal and weak fashion. There was no immunoreactivity with CD56, p63, or HMWCK. Ki-67 highlighted only rare nuclei (<1 %). No neuroendocrine granules were demonstrated by electron microscopy in four cases that showed no immunoreactivity for neuroendocrine markers. In summary, SCLC is more frequently found in high-grade prostate cancer, but it may also be encountered as a noninvasive lesion in Gleason score 6 (grade group 1) cancer. Importantly, it does not appear to indicate neuroendocrine differentiation. The low-grade cytology, the lack of mitoses and apoptoses, and the minimal Ki-67 reactivity are findings to support its discrimination from a small cell carcinoma.

Entities:  

Keywords:  Cancer; Intraductal; Prostate; Small cell-like

Mesh:

Substances:

Year:  2016        PMID: 27743032     DOI: 10.1007/s00428-016-2033-7

Source DB:  PubMed          Journal:  Virchows Arch        ISSN: 0945-6317            Impact factor:   4.064


  23 in total

1.  Best practices recommendations in the application of immunohistochemistry in the prostate: report from the International Society of Urologic Pathology consensus conference.

Authors:  Jonathan I Epstein; Lars Egevad; Peter A Humphrey; Rodolfo Montironi
Journal:  Am J Surg Pathol       Date:  2014-08       Impact factor: 6.394

Review 2.  Genitourinary small cell malignancies: prostate and bladder.

Authors:  Kashyap Shatagopam; Hristos Z Kaimakliotis; Liang Cheng; Michael O Koch
Journal:  Future Oncol       Date:  2015       Impact factor: 3.404

3.  Prostate Cancer Grading: A Decade After the 2005 Modified Gleason Grading System.

Authors:  Oleksandr N Kryvenko; Jonathan I Epstein
Journal:  Arch Pathol Lab Med       Date:  2016-01-12       Impact factor: 5.534

4.  Anastomosing hemangioma of the genitourinary system: eight cases in the kidney and ovary with immunohistochemical and ultrastructural analysis.

Authors:  Oleksandr N Kryvenko; Nilesh S Gupta; Frederick A Meier; Min W Lee; Jonathan I Epstein
Journal:  Am J Clin Pathol       Date:  2011-09       Impact factor: 2.493

Review 5.  The 2014 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of Prostatic Carcinoma: Definition of Grading Patterns and Proposal for a New Grading System.

Authors:  Jonathan I Epstein; Lars Egevad; Mahul B Amin; Brett Delahunt; John R Srigley; Peter A Humphrey
Journal:  Am J Surg Pathol       Date:  2016-02       Impact factor: 6.394

6.  The formaldehyde-fixed and paraffin-embedded tissues for diagnostic transmission electron microscopy: a retrospective and prospective study.

Authors:  N S Wang; H Minassian
Journal:  Hum Pathol       Date:  1987-07       Impact factor: 3.466

7.  Cyclin D1 Loss Distinguishes Prostatic Small-Cell Carcinoma from Most Prostatic Adenocarcinomas.

Authors:  Harrison Tsai; Carlos L Morais; Mohammed Alshalalfa; Hsueh-Li Tan; Zaid Haddad; Jessica Hicks; Nilesh Gupta; Jonathan I Epstein; George J Netto; William B Isaacs; Jun Luo; Rohit Mehra; Robert L Vessella; R Jeffrey Karnes; Edward M Schaeffer; Elai Davicioni; Angelo M De Marzo; Tamara L Lotan
Journal:  Clin Cancer Res       Date:  2015-08-05       Impact factor: 12.531

Review 8.  Small cell carcinoma of the prostate.

Authors:  Rosa Nadal; Michael Schweizer; Oleksandr N Kryvenko; Jonathan I Epstein; Mario A Eisenberger
Journal:  Nat Rev Urol       Date:  2014-02-18       Impact factor: 14.432

9.  Small cell carcinoma of the prostate. II. Immunohistochemical and electron microscopic studies of 18 cases.

Authors:  J Y Ro; B Têtu; A G Ayala; N G Ordóñez
Journal:  Cancer       Date:  1987-03-01       Impact factor: 6.860

10.  A Contemporary Prostate Cancer Grading System: A Validated Alternative to the Gleason Score.

Authors:  Jonathan I Epstein; Michael J Zelefsky; Daniel D Sjoberg; Joel B Nelson; Lars Egevad; Cristina Magi-Galluzzi; Andrew J Vickers; Anil V Parwani; Victor E Reuter; Samson W Fine; James A Eastham; Peter Wiklund; Misop Han; Chandana A Reddy; Jay P Ciezki; Tommy Nyberg; Eric A Klein
Journal:  Eur Urol       Date:  2015-07-10       Impact factor: 20.096

View more
  1 in total

1.  A potential biomarker hsa-miR-200a-5p distinguishing between benign thyroid tumors with papillary hyperplasia and papillary thyroid carcinoma.

Authors:  Xian Wang; Shan Huang; Xiaocan Li; Dongrui Jiang; Hongzhen Yu; Qiang Wu; Chaobing Gao; Zhengsheng Wu
Journal:  PLoS One       Date:  2018-07-13       Impact factor: 3.240

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.